In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
News|Podcasts|November 25, 2025
ACT Brief: AI-Driven Pharmacovigilance, Site-Led Digital Investments, and Smarter Multi-Touch Recruitment
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we examine how AI and functional service partners are reshaping global pharmacovigilance, look at new data on how investigative sites are investing in and integrating digital solutions, and explore how Trialbee assesses ROI across emerging multi-touch recruitment platforms.
This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.
- A new feature
article details how AI-enabled automation is moving firmly into routine pharmacovigilance operations. Sponsors are now using AI-supported intake, triage, and case processing to handle rising safety case volumes and reduce manual inefficiencies—while preserving expert judgment for nuanced clinical decisions. The piece also highlights how functional service provider partners are becoming essential for scaling these technologies, helping sponsors integrate flexible, transparent, and auditable AI workflows without adding heavy internal infrastructure. - A new Tufts CSDD
study shows that investigative sites have far more digital capability and experience than long assumed. Many sites have invested in their own validated tools—often integrated directly with electronic health records—to support remote monitoring, ePROs, telehealth visits, and decentralized workflows. But sponsors and CROs aren’t always aware of these existing site systems, contributing to the fragmentation and burden sites continue to face. The findings reinforce a key message for clinical operations leaders: site-driven digital infrastructure is real, mature, and should be better integrated into study planning. - And in the final part of our video series with Trialbee, Christian Bullock
discusses how teams measure ROI and platform effectiveness in multi-touch digital recruitment. He explains why emerging platforms such as TikTok, Reddit, Spotify, and Nextdoor must be evaluated within the context of the full recruitment funnel—not just last-touch conversions. Bullock emphasizes the importance of tracking engagement, understanding return visits, and continuously testing creative and audience segments to optimize performance while meeting compliance expectations.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
Trending on Applied Clinical Trials Online
1
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
2
FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations
3
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
4
Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success
5